Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”

Pazopanib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic renal cell carcinoma (mRCC) and soft tissue sarcoma. The present study analyzed the outcomes of pazopanib in first-line treatment of mRCC, in a single Italian cancer center. In the light of the retrospective,...

Descripción completa

Detalles Bibliográficos
Autores principales: Cecere, Sabrina C., Rossetti, Sabrina, Cavaliere, Carla, Della Pepa, Chiara, Di Napoli, Marilena, Crispo, Anna, Iovane, Gelsomina, Piscitelli, Raffaele, Sorrentino, Domenico, Ciliberto, Gennaro, Maiolino, Piera, Muto, Paolo, Perdonà, Sisto, Berretta, Massimiliano, Pignata, Sandro, Facchini, Gaetano, D'Aniello, Carmine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005368/
https://www.ncbi.nlm.nih.gov/pubmed/27630568
http://dx.doi.org/10.3389/fphar.2016.00287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005368/
https://www.ncbi.nlm.nih.gov/pubmed/27630568
http://dx.doi.org/10.3389/fphar.2016.00287

Ejemplares similares